Gilda Porta

机构：Dr. Euryclides Hospital de Jesus Zerbini, Hospital Sírio-Libanês, Hospital São Paulo · ORCID：0000-0002-0274-6274

发表论文 274 篇 · 总被引 9893 次 · h-index 42

代表论文

• Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2024 · ˜The œLancet. Gastroenterology & hepatology · 被引 60)
• An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease (2024 · Med · 被引 53)
• Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021 (2024 · Clinical Nutrition · 被引 46)
• A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease (2024 · Hepatology International · 被引 33)
• FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease (2024 · Journal of Pediatric Gastroenterology and Nutrition · 被引 9)
• Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model (2024 · JCI Insight · 被引 8)